

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

ESPERION THERAPEUTICS INC/MI
Form 10-Q
November 09, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended: SEPTEMBER 30, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number: 001-16033

ESPERION THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State of incorporation)

38-3419139
(IRS Employer Identification No.)

3621 S. STATE STREET, 695 KMS PLACE
ANN ARBOR, MI 48108
(734) 332-0506
(Address of principal executive offices, including zip
code, and telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes

No

The number of outstanding shares of the Registrant's common stock, as of
November 2, 2001, was 29,169,835.

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

ESPERION THERAPEUTICS, INC.

FORM 10-Q
TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2001 and
December 31, 2000.....

Condensed Consolidated Statements of Operations for the Three and
Nine Months Ended September 30, 2001 and 2000, and the period
from inception to September 30, 2001.....

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September
2001 and 2000, and the period from inception to September 30, 2001.....

Notes to Condensed Consolidated Financial Statements.....

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....

Item 3. Quantitative and Qualitative Disclosures about Market Risk.....

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.....

Item 2. Changes in Securities and Use of Proceeds.....

Item 3. Defaults Upon Senior Securities.....

Item 4. Submission of Matters to a Vote of Security Holders.....

Item 5. Other Information.....

Item 6. Exhibits and Reports on Form 8-K.....

SIGNATURES.....

INDEX TO EXHIBITS.....

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

ITEM 1. FINANCIAL STATEMENTS

ESPERION THERAPEUTICS, INC. AND SUBSIDIARIES (A Company in the Development Stage)

CONDENSED CONSOLIDATED BALANCE SHEETS

in thousands	September 30, 2001	December 31, 2000

(Unaudited)		
ASSETS:		
Current assets:		
Cash and cash equivalents	\$ 76,985	\$ 70,228
Prepaid expenses and other	840	1,112

Total current assets	77,825	71,340

Furniture and equipment, net	3,400	2,503
Goodwill, net	3,317	3,500
Deposits and other assets	421	534

Total assets	\$ 84,963	\$ 77,877
=====		
LIABILITIES AND STOCKHOLDERS' EQUITY:		
Current liabilities:		
Current portion of long-term debt	\$ 952	\$ 697
Accounts payable	2,621	3,936
Accrued liabilities	3,247	2,526

Total current liabilities	6,820	7,159

Long-term debt, less current portion	5,386	3,027
Stockholders' equity:		
Common stock	29	26
Additional paid-in capital	133,575	110,650
Notes receivable	(18)	(67)
Accumulated deficit during the development stage	(58,976)	(40,389)
Deferred stock compensation	(2,012)	(2,774)
Accumulated other comprehensive income	159	245

Total stockholders' equity	72,757	67,691

Total liabilities and stockholders' equity	\$ 84,963	\$ 77,877
=====		

The accompanying notes are an integral part
of these condensed consolidated financial statements.

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

ESPERION THERAPEUTICS, INC. AND SUBSIDIARIES
(A Company in the Development Stage)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended September 30,		Nine Sep
in thousands except share and per share data	2001	2000	2001
<hr style="border-top: 1px dashed black;"/>			
Operating expenses:			
Research and development	\$ 4,902	\$ 6,701	\$ 16,300
General and administrative	1,395	611	3,730
Goodwill amortization	210	63	630
Purchased in-process research and development	0	4,000	
<hr style="border-top: 1px dashed black;"/>			
Total operating expenses	6,507	11,375	20,660
<hr style="border-top: 1px dashed black;"/>			
Operating loss	(6,507)	(11,375)	(20,660)
<hr style="border-top: 1px dashed black;"/>			
Other income (expense):			
Interest income	679	782	2,350
Interest expense	(228)	(157)	(540)
Other, net	(225)	(54)	260
<hr style="border-top: 1px dashed black;"/>			
Total other income	226	571	2,070
<hr style="border-top: 1px dashed black;"/>			
Loss before income taxes	(6,281)	(10,804)	(18,580)
Provision for income taxes	0	0	
<hr style="border-top: 1px dashed black;"/>			
Net loss	(6,281)	(10,804)	(18,580)
Beneficial conversion feature on preferred stock	0	0	
<hr style="border-top: 1px dashed black;"/>			
Net loss attributable to common stockholders	(\$6,281)	(\$10,804)	(\$18,580)
<hr style="border-top: 1px dashed black;"/>			
Basic and diluted net loss per common share	(\$0.22)	(\$0.74)	(\$0.74)
<hr style="border-top: 1px dashed black;"/>			
Weighted average common shares	28,177,102	14,670,614	26,675,590
<hr style="border-top: 1px dashed black;"/>			
Basic and diluted net loss per share attributable to common stockholders	(\$0.22)	(\$0.74)	(\$0.74)
<hr style="border-top: 1px dashed black;"/>			
Weighted average common shares	28,177,102	14,670,614	26,675,590
<hr style="border-top: 1px dashed black;"/>			
Pro forma basic and diluted net loss per common share		(\$0.50)	
<hr style="border-top: 1px dashed black;"/>			
Pro forma weighted average common shares		21,699,485	
<hr style="border-top: 1px dashed black;"/>			
Pro forma basic and diluted net loss per share attributable to common stockholders		(\$0.50)	
<hr style="border-top: 1px dashed black;"/>			

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

Pro forma weighted average common shares

21,699,485
=====

The accompanying notes are an integral part
of these condensed consolidated financial statements.

4

ESPERION THERAPEUTICS, INC. AND SUBSIDIARIES (A Company in the Development Stage)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

in thousands	Nine Months Ended September 30,		Inception to September 30,
	2001	2000	2001
<hr/>			
Cash flows from operating activities:			
Net loss	(\$18,587)	(\$22,011)	(\$58,976)
Adjustments to reconcile net loss to net cash used in operating activities:			
Purchased in-process research and development	0	4,000	4,000
Depreciation and amortization	2,209	1,342	5,010
Stock-based compensation expense	0	413	688
Decrease in notes receivable	49	32	108
Loss on sale of furniture and equipment	22	0	22
Non-cash interest included in long-term debt	171	108	331
Changes in assets and liabilities:			
Prepaid expenses and other	(320)	(642)	(1,714)
Other assets	(7)	(110)	(92)
Accounts payable	(1,130)	1,280	2,884
Accrued liabilities	860	3,484	3,275
<hr/>			
Net cash used in operating activities	(16,733)	(12,104)	(44,464)
<hr/>			
Cash flows from investing activities:			
Purchases of furniture and equipment	(1,259)	(785)	(5,027)
Deposit on furniture and equipment	(382)	(450)	(832)
Acquisition of Talaria Therapeutics, Inc.	0	(233)	(233)
Proceeds from sale of furniture and equipment	2	0	2
<hr/>			
Net cash used in investing activities	(1,639)	(1,468)	(6,090)
<hr/>			
Cash flows from financing activities:			
Net proceeds from issuance of convertible preferred stock	0	26,871	42,200
Proceeds from the issuance of common stock	22,481	56,337	78,759
Proceeds from long-term debt	3,409	781	7,925
Repayments of long-term debt	(689)	(450)	(1,455)
<hr/>			
Net cash provided by financing activities	25,201	83,539	127,429
<hr/>			
Effect of exchange rate changes on cash	(72)	(233)	110

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

Net increase (decrease) in cash and cash equivalents	6,757	69,734	76,985
Cash and cash equivalents at beginning of period	70,228	5,904	0
<hr/>			
Cash and cash equivalents at end of period	\$ 76,985	\$ 75,638	\$ 76,985
<hr/>			
Supplemental disclosures of cash flow information:			
Cash paid during the period for:			
Interest	\$ 362	\$ 256	
Income taxes	\$ 0	\$ 0	
<hr/>			

The accompanying notes are an integral part
of these condensed consolidated financial statements.

5

ESPERION THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Esperion Therapeutics, Inc. ("Esperion" or the "Company") and its subsidiaries, and have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. The Company believes that all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The information included in this Form 10-Q should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2000.

Operating results for the three- and nine-month periods ended September 30, 2001 and 2000 are not necessarily indicative of the results that may be expected for the full year.

(2) - PRIVATE PLACEMENT OF COMMON STOCK

In July 2001, the Company completed a private placement of its stock, which resulted in the issuance of 3,183,335 shares of common stock at \$7.50 per share. The net proceeds from the private placement approximated \$22.3 million. In August 2001, the Company filed a Registration Statement to register these shares under the Securities Act of 1933, as amended. The Registration Statement was declared effective by the Securities and Exchange Commission on September 4, 2001.

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

(3) - COMPREHENSIVE LOSS

Comprehensive loss is the total of net loss and all other non-owner changes in equity. Total comprehensive loss was \$6,285,000 and \$10,555,000 for the three-month periods ended September 30, 2001 and 2000, respectively, and \$18,501,000 and \$21,768,000, for the nine-month periods ended September 30, 2001 and 2000, respectively. The difference between net loss, as reported in the accompanying condensed consolidated statements of operations, and comprehensive loss is the foreign currency translation adjustment for the respective periods.

(4) - BASIC, DILUTED AND PRO FORMA LOSS PER SHARE

Basic and diluted net loss per share amounts have been calculated using the weighted average number of shares of common stock outstanding during the respective periods. Options for the purchase of 764,938 and 1,092,727 shares of common stock, for the three-month periods ended September 30, 2001 and 2000, respectively, and 760,994 and 1,023,928 for the nine-month periods ended September 30, 2001 and 2000, respectively, were not included in the calculation of diluted net loss per share as doing so would have been anti-dilutive.

Pro forma basic and diluted net loss per share includes the shares used in computing basic and diluted net loss per share and the assumed conversion of all outstanding shares of preferred stock from the original date of issuance.

6

ESPERION THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)

The following table presents the calculation of pro forma basic and diluted net loss per share:

	Three Months Ended September 30, 2000 -----	Nine Months Ended September 30, 2000 -----
Net loss attributable to common stockholders	\$(10,804,000) =====	\$(44,881,000) =====
Shares used in computing basic and diluted net loss per share	14,670,614	6,285,788
Pro forma adjustment to reflect assumed conversion of Series A and Series B preferred stock	3,371,664	6,181,384
Pro forma adjustment to reflect assumed conversion of Series C and Series D preferred stock	3,657,207 -----	6,354,706 -----
Shares used in computing pro forma basic and diluted net loss per share	21,699,485 =====	18,821,878 =====
Pro forma basic and diluted net loss per share	\$ (0.50)	\$ (2.38)

=====

(5) - COMMITMENTS AND CONTINGENCIES

Contingent repurchase of stock

The Company may be required to repurchase approximately 47,000 shares of common stock that were sold to certain employees and others under the Company's directed share program as part of the initial public offering. The Company believes that the maximum liability arising from this repurchase would be approximately \$423,000 plus interest. A liability has not been recorded in the financial statements, as management believes that the potential repurchase of these shares is not likely.

(6) - NEW ACCOUNTING PRONOUNCEMENTS

In July 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, "Business Combinations" ("SFAS 141") and No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). In August 2001, the Financial Accounting Standards Board issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144").

SFAS 141 supersedes Accounting Principles Board Opinion No. 16, "Business Combinations". The most significant changes made by SFAS 141 are (1) requiring that the purchase method of accounting be used for all business combinations initiated after June 30, 2001, (2) establishing specific criteria for the recognition of intangible assets separately from goodwill, and (3) requiring unallocated negative goodwill to be written off immediately as an extraordinary gain (rather than being deferred and amortized).

SFAS 142 supersedes Accounting Principles Board Opinion No. 17, "Intangible Assets", and primarily addresses the accounting for goodwill and intangible assets subsequent to their acquisition. The most significant changes made by SFAS 142 are that: (1) goodwill and indefinite lived intangible assets will no longer be amortized, (2) goodwill will be tested for impairment at least annually at the reporting level, (3) intangible assets deemed to have an indefinite life will be tested for impairment at least annually, and (4) the amortization of intangible assets with finite lives will no longer be limited to forty years. SFAS 142 also specifies that certain intangible assets that were

previously identified as separate from goodwill (i.e., assembled workforce) are not considered separately identifiable for purposes of this standard and should be included as part of goodwill and subject to the non-amortization provisions for SFAS 142.

The provisions for SFAS 142 will be effective for the Company's fiscal year beginning January 1, 2002. At effectiveness, an evaluation of goodwill will be required, and any impairment of goodwill at that time will be recognized as a cumulative effect of adoption. Total goodwill included in the Company's Consolidated Financial Statements was \$3.3 million at September 30, 2001 and \$3.5 million at December 31, 2000. Goodwill amortization expense was \$210,000 and \$63,000 for the three-month periods ended September 30, 2001 and 2000, respectively. Goodwill amortization expense was \$630,000 and \$63,000 for the nine-month periods ended September 30, 2001 and 2000, respectively. As a result

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

of the non-amortization provisions of SFAS 142, the Company expects reported net loss to decrease subsequent to the effectiveness of SFAS 142. In addition, based on management's current financial projections, management does not believe that goodwill and other intangibles are currently impaired. The Company will perform a more detailed assessment to determine the effect of this new standard.

SFAS 144 supersedes SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of" and the accounting and reporting provisions of APB Opinion No. 30, "Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions" for the disposal of a segment of a business (as previously defined in that Opinion). SFAS 144 is effective for the Company's fiscal year beginning January 1, 2002 and is not expected to have a material impact upon effectiveness.

8

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion provides an analysis of the Company's condensed financial condition and results of operations, and should be read in conjunction with the Company's consolidated financial statements and the notes included in Item 1 of this Form 10-Q.

FORWARD-LOOKING INFORMATION IS SUBJECT TO RISK AND UNCERTAINTY

The following Management's Discussion and Analysis of Financial Condition and Results of Operations as well as information contained elsewhere in this report contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are often identified by words such as "may," "believe," "anticipate," "planned," "expect," "require," "intend," "assume," and similar expressions. Our forward-looking statements involve uncertainties and other factors that may cause our actual results, performance or achievements to be far different from those suggested by our forward-looking statements. These factors include, but are not limited to, risks associated with the development of our product candidates, including regulatory approval; dependence on contract research organizations, license arrangements and other strategic relationships with third parties for the research, development, manufacturing and commercialization of our products; dependence on patents and proprietary rights; procurement, maintenance, enforcement and defense of the Company's patents and proprietary rights; risks related to manufacturing; risks associated with the timing and acceptance of new products by the Company or its competitors; competitive conditions in the industry; business cycles affecting the markets in which the Company's products are sold; extraordinary events, such as litigation; risks inherent in seeking and consummating acquisitions, including the diversion of management attention to the assimilation of the operations and personnel of the acquired business; risks relating to the timing of the Company's financing needs; fluctuations in foreign exchange rates; and economic conditions generally or in various geographic areas. All of the foregoing factors are difficult to forecast. More detailed information about these and other factors is set forth in our other filings with the Securities and Exchange Commission. We do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or circumstances.

OVERVIEW

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

Background

We have devoted substantially all of our resources since we began our operations in May 1998 to the research and development of pharmaceutical product candidates for cardiovascular and metabolic diseases. We are a development stage pharmaceutical company and have not generated any revenues from product sales. We have not been profitable and have incurred a cumulative net loss of approximately \$59.0 million from inception through September 30, 2001. These losses have resulted principally from costs incurred in research and development activities, and general and administrative expenses. We expect to incur significant additional operating losses for at least the next several years and until such time as we generate sufficient revenue to offset expenses. Also, we anticipate that research and development costs relating to product candidates will increase. Finally, we expect to have increasing development, manufacturing, sales and marketing costs as we prepare for the commercialization of our product candidates.

9

RESULTS OF OPERATIONS

Operating Expenses

dollars in thousands	Three Months Ended September 30,			Nine Months
	2001	2000	% Change	2001
Research and development	\$4,902	\$6,701	-26.8%	\$16,303
% of total	75.4%	58.9%		78.9%
General and administrative	\$1,395	\$611	128.3%	\$3,732
% of total	21.4%	5.4%		18.1%
Goodwill amortization	\$210	\$63	233.3%	\$630
% of total	3.2%	0.6%		3.0%
Purchased in-process R&D	\$0	\$4,000	-100.0%	\$0
% of total	0.0%	35.1%		0.0%

Three Months Ended September 30, 2001 and 2000

Research and Development Expenses. Research and development expenses include both external and internal costs related to the research and development activities of our existing product candidates as well as discovery efforts on potential new product candidates. External costs include costs related to manufacturing, clinical trials, toxicology or pharmacology studies performed by third parties, milestone payments under certain license agreements and other related expenses. Internal costs include all payroll and related costs attributable to research and development activities, as well as an allocation of

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

overhead expenses incurred by the Company. Research and development expenses decreased to approximately \$4.9 million for the three months ended September 30, 2001 compared to approximately \$6.7 million for the three months ended September 30, 2000. This 26.8% decrease is primarily due to lower manufacturing and other costs related to clinical trials, as well as lower costs related to pre-clinical development of our biopharmaceutical product candidates in the third quarter of 2001. During the third quarter of 2000, the Company had certain costs associated with one clinical trial and contract manufacturing costs related to three of its product candidates. Many of these costs were not recurring in the third quarter of 2001. The magnitude of the Company's operating expenses, particularly research and development expense, is largely dependant upon the timing and size of the clinical trials. As additional clinical trials begin in the fourth quarter of this year and into next year, the Company anticipates research and development expenses will increase over current quarter levels.

General and Administrative Expenses. General and administrative expenses include the cost of salaries, employee benefits, and other costs associated with the Company's finance, accounting, human resources, legal, administrative and executive management functions. General and administrative expenses also include an allocation of overhead expenses incurred by the Company. General and administrative expenses increased to approximately \$1.4 million for the three months ended September 30, 2001 compared to approximately \$611,000 for the three months ended September 30, 2000. This 128.3% increase resulted from higher payroll, overhead and related costs in support of the Company's anticipated growing research and development activities as compared to the prior year. Included in this increase are costs related to a market research study performed by a third party to provide the Company with some preliminary assessment about product positioning and market potential of certain product candidates.

Goodwill Amortization. Goodwill amortization reflects the amortization of the amount of the excess of the purchase price over net assets in the Company's September 2000 acquisition of Talaria Therapeutics, Inc. ("Talaria") and the milestone payments made to date. Total goodwill included in the Company's Consolidated Financial

10

Statements was \$3.3 million at September 30, 2001 and \$3.5 million at December 31, 2000. Goodwill amortization expense was \$210,000 and \$63,000 for the three months ended September 30, 2001 and 2000, respectively. Goodwill amortization expense was \$630,000 and \$63,000 for the nine months ended September 30, 2001 and 2000, respectively. The increase in goodwill amortization is a result of higher goodwill upon the achievement of certain LUV clinical development milestones as well as the timing of the acquisition of Talaria. The Company is amortizing this goodwill over five years, which represents the period estimated to be benefited from the acquisition, after considering such factors as product development timelines, revenue potential, competition and patent life.

In July 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 142, Goodwill and Other Intangible Assets" ("SFAS 142"), which primarily addresses the accounting for goodwill and intangible assets subsequent to their acquisition. The provisions for SFAS 142 will be effective for the Company's fiscal year beginning January 1, 2002. This statement is summarized in Note 6 of Notes to Consolidated Financial Statements.

Purchased in-process research and development. Purchased in-process research and development in 2000 represents a \$4.0 million one-time charge to operations

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

in connection with the acquisition of Talaria in September 2000. This represents the write-off of acquired in-process research and development that had not reached technological feasibility. The allocation of the purchase price was based on an independent appraisal of the fair values on the closing date.

Other Income, Net. Other income, net consists of interest income (expense), foreign currency transaction loss, and gain (loss) on the disposal of property and equipment. Interest income decreased to approximately \$679,000 for the three months ended September 30, 2001 compared to approximately \$782,000 for the three months ended September 30, 2000. The decrease is primarily attributable to lower interest rates in 2001 compared to the same period last year. Interest expense for the three months ended September 30, 2001 and 2000 was approximately \$228,000 and \$157,000, respectively, and represents interest incurred on equipment financing facilities and a special project loan. The increase in interest expense resulted from higher outstanding borrowings in 2001 as compared to the comparable period in 2000. During the three months ended September 30, 2001 and 2000, we recorded approximately \$179,000 and \$54,000, respectively, of foreign currency transaction losses on transactions denominated in various currencies of European countries.

Net Loss. The net loss was approximately \$6.3 million for the three months ended September 30, 2001 compared to approximately \$10.8 million for the three months ended September 30, 2000. The decrease in net loss resulted from lower research and development expenses, offset in part by the increases in general and administrative expenses. In addition, the net loss for the three months ended September 30, 2000 includes the \$4.0 million one-time charge related to purchased in-process research and development.

Nine Months Ended September 30, 2001 and 2000

Research and Development Expenses. Research and development expenses include both external and internal costs related to the research and development activities of our existing product candidates as well as discovery efforts on potential new product candidates. External costs include costs related to manufacturing, clinical trials, toxicology or pharmacology studies performed by third parties, milestone payments under certain license agreements and other related expenses. Internal costs include all payroll and related costs attributable to research and development activities, as well as an allocation of overhead expenses incurred by the Company. Research and development expenses decreased to approximately \$16.3 million for the nine months ended September 30, 2001 compared to approximately \$16.9 million for the nine months ended September 30, 2000. This 3.3% decrease is primarily due to lower manufacturing and other costs related to clinical trials, as well as lower costs related to pre-clinical development of our biopharmaceutical product candidates during 2001. During the third quarter of 2000, the Company had certain costs associated with one clinical trial and contract manufacturing costs related to three of its product candidates. Many of these costs were not recurring in the third quarter of 2001. The magnitude of the Company's operating expenses, particularly research and development expense, is largely dependant upon the timing and size of the clinical trials. As additional clinical trials begin in the fourth quarter of this year and into next year, the Company anticipates research and development expenses will increase over current quarter levels.

General and Administrative Expenses. General and administrative expenses include the cost of salaries, employee benefits, and other costs associated with the Company's finance, accounting, human resources, legal, administrative and executive management functions. General and administrative expenses also include

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

an allocation of overhead expenses incurred by the Company. General and administrative expenses increased to approximately \$3.7 million for the nine months ended September 30, 2001 compared to approximately \$2.3 million for the nine months ended September 30, 2000. This 59.7% increase resulted from higher payroll, overhead and related costs in support of the Company's growing research and development activities as compared to the prior year. Included in this increase are costs related to a market research study performed by a third party to provide the Company with some preliminary assessment about product positioning and market potential of certain product candidates.

Other Income, Net. Other income, net consists of interest income (expense), foreign currency transaction gain, and the loss on the disposal of property and equipment. Interest income increased to approximately \$2.4 million for the nine months ended September 30, 2001 compared to approximately \$1.4 million for the nine months ended September 30, 2000. The increase is attributable to higher levels of cash and cash equivalents available for investment in 2001 as a result of the cash raised in the Company's initial public offering in August 2000, as well as the private placement in July 2001. This increase was partially offset by lower interest rates on these investments. Interest expense for the same periods was approximately \$540,000 and \$333,000, respectively, and represents interest incurred on the higher amount of borrowings under the equipment financing facilities and a special project loan. The increase in interest expense resulted from higher outstanding borrowings in 2001 as compared to the comparable period in 2000. During the nine months ended September 30, 2001 and 2000, we recorded approximately \$340,000 and \$143,000, respectively, of foreign currency transaction gains on transactions denominated in various currencies of European countries.

Net Loss. The net loss was approximately \$18.6 million for the nine months ended September 30, 2001 compared to approximately \$22.0 million for the nine months ended September 30, 2000. The decrease in net loss resulted from lower research and development offset in part by general and administrative expenses. In addition, the net loss for the three months ended September 30, 2000 includes the \$4.0 million one-time charge related to purchased in-process research and development.

Net Loss Attributable to Common Stockholders. The net loss attributable to common stockholders for the nine months ended September 30, 2000 includes a one-time \$22.9 million charge related to the beneficial conversion feature on the series C and series D convertible preferred stock. The total of the non-cash beneficial conversion feature was reflected through equal and offsetting adjustments to additional paid-in-capital with no net impact on stockholders' equity. The beneficial conversion feature was considered in the determination of our loss per common share amounts.

LIQUIDITY AND CAPITAL RESOURCES

In July 2001, the Company issued 3,183,335 shares of common stock at \$7.50 per share in a private placement. Net proceeds to the Company from the private placement were approximately \$22.3 million, after deducting expenses related to the issuance.

In August 2000, the Company completed an initial public offering of its stock, which resulted in the issuance of 6,000,000 shares of common stock at \$9.00 per share. In September 2000, an additional 900,000 shares were sold by the Company at \$9.00 per share to cover the underwriters' over-allotment. Net proceeds to the Company from the offering were approximately \$56.2 million, after deducting the underwriting discount and offering expenses.

As of September 30, 2001, the Company had cash and cash equivalents of approximately \$77.0 million. Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

investments that maximize interest income to the extent possible by investing cash in short-term, investment-grade, interest-bearing securities. We believe that our current cash position, along with available borrowings under our

12

credit facilities will be sufficient to fund our operations and capital expenditures for at least the next twelve months. We anticipate that our capital expenditures for the next twelve months will be approximately \$2.5 million.

During the nine months ended September 30, 2001 and 2000, net cash used in operating activities was approximately \$16.7 million and \$12.1 million, respectively. This cash was used to fund our net losses for the periods, adjusted for non-cash expenses and changes in operating assets and liabilities.

Net cash used in investing activities for the nine months ended September 30, 2001 and 2000 was approximately \$1.6 million and \$1.5 million, respectively. The net cash used in investing activities for the nine months ended September 30, 2001 and 2000 resulted primarily from the acquisition of laboratory equipment, furniture and fixtures and office equipment. The Company also used approximately \$233,000 in cash related to the acquisition of Talaria in September 2000.

Net cash proceeds from financing activities were \$25.2 million and \$83.5 million for the nine months ended September 30, 2001 and 2000, respectively. The net cash proceeds from financing activities for the nine months ended September 30, 2001 resulted primarily from \$22.3 million raised in the private placement, \$3.4 million of additional borrowings on the special project loan and equipment term loans, and \$139,000 raised from the issuance of common stock to employees as part of the Company's equity compensation plans. The proceeds were partially offset by \$689,000 of cash used to repay borrowings under equipment loans. Also, the Company issued 58,626 shares of common stock to Talaria stockholders for the payment of a milestone achieved in January 2001. The net cash proceeds from financing activities for the nine months ended September 30, 2000 resulted primarily from \$56.2 million raised in the initial public offering, \$26.9 million raised in preferred stock financings, \$781,000 of additional borrowings on a special project loan, and \$84,000 raised from the issuance of common stock to employees as part of the Company's equity compensation plans. The proceeds were partially offset by \$450,000 of cash used to repay borrowings under an equipment loan.

As of September 30, 2001, we had approximately \$372,000 outstanding under an equipment term loan with a U.S. bank. Borrowings under the term loan bear interest at the bank's prime rate plus 1.0%. Also, we have a second equipment term loan with another U.S. bank. Outstanding borrowings under this equipment term loan have a weighted average interest rate of approximately 12% per annum and amounted to approximately \$2.0 million as of September 30, 2001. We also have a memorandum of understanding with respect to entering into an equipment loan with an economic development group whereby we may borrow up to \$500,000 for equipment purchases. Outstanding borrowings under the term loan bear interest at 4% per annum and total approximately \$268,000 as of September 30, 2001. In addition, we have a special project loan with a Swedish entity with outstanding borrowings totaling 37 million Swedish kronor (approximately \$3.7 million of which was outstanding as of September 30, 2001) that may only be used to finance the development of our AIM product candidate. If a related product is not developed or does not succeed in the market, our obligation to repay the loan may be forgiven. Borrowings under the Swedish credit facility bear interest at 17.0% per annum, of which 9.5% is payable quarterly. The remaining 7.5% of

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

interest together with principal are payable in five equal annual installments starting December 2004. The Company has 13 million Swedish kronor (approximately \$1.3 million as of September 30, 2001) available under this special project loan that is available upon the achievement of certain product development milestones.

We lease our corporate and research and development facilities under operating leases expiring at various times through December 2003. Minimum annual payments under these leases for the next twelve months are approximately \$701,000 as of September 30, 2001.

We expect that our operating expenses and capital expenditures will increase in future periods in part because of our intent to hire additional research and development, clinical testing and administrative staff. Our capital expenditure requirements will depend on numerous factors, including the progress of our research and development programs, the time required to file and process regulatory approval applications, the development of commercial manufacturing capability, the ability to obtain additional licensing arrangements, and the demand for our product candidates, if and when approved by the FDA or other regulatory authorities.

13

INCOME TAXES

As of September 30, 2001, we had operating loss carryforwards of approximately \$40.6 million. These net operating loss carryforwards begin to expire in 2013. Additionally, utilization of net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code. These and other deferred income tax assets are fully reserved by a valuation allowance.

EMPLOYEES

As of September 30, 2001, we had 71 full-time employees. Of these employees, 55 were engaged in research, preclinical and clinical development, regulatory affairs, intellectual property activities, and/or manufacturing activities and 16 were engaged in general and administrative activities.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure to market risk for changes in interest rates relates primarily to the increase or decrease in the amount of interest income we can earn on our investment portfolio and on the increase or decrease in the amount of interest expense we must pay with respect to our various outstanding debt instruments. Under our current policies, we do not use interest rate derivative instruments to manage our exposure to interest rate changes. We ensure the safety and preservation of our invested principal funds by limiting default risks, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. A hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments at September 30, 2001. Declines in interest rates over time will, however, reduce our interest income while increases in interest rates over time will increase our interest expense. Although currency fluctuations are currently not a material risk to our operating results, we have and will continue to monitor our exposure to currency fluctuations and when appropriate, we may use financial hedging techniques to

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

minimize the effect of these fluctuations in the future. We cannot ensure that exchange rate fluctuations will not harm our business in the future.

14

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Not applicable.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

On July 25, 2001, the Company completed a private placement of 3,183,335 shares of common stock for \$7.50 per share, raising net proceeds of approximately \$22.3 million. The Company relied on an exemption from registration under the Securities Act of 1933, as amended, based upon the offer and sale of the securities only to accredited investors. In August 2001, the Company filed a Registration Statement to register these shares under the Securities Act of 1933, as amended. The Registration Statement was declared effective by the Securities and Exchange Commission on September 4, 2001. In August 2000, the Company completed an initial public offering of its common stock, raising net proceeds of approximately \$56.2 million. The Company invested the net proceeds from the private placement and the initial public offering in short-term, investment-grade, interest-bearing securities. These proceeds, as well as proceeds from earlier private placements, are being used to fund research and development, payments under current licensing agreements, and for other working capital and general corporate purposes, including employee compensation.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

15

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

Edgar Filing: ESPERION THERAPEUTICS INC/MI - Form 10-Q

(A) EXHIBITS

NUMBER	EXHIBIT
10.33	Commercial Sublease between SWMF Holdings Corporation and Esperion Therapeutics, June 22, 2001.
10.34	Lease Extension - Second Renewal Term between Maxey LLC and Esperion Therapeutics September 21, 2001.
10.35@	License Agreement Michigan File 1855 Technology between the Regents of the University of Michigan and Esperion Therapeutics, Inc. dated effective September 18, 2001.

@ Confidential treatment has been requested with respect to the portions of the Agreement indicated with brackets and asterisks [***]. A complete copy of this Agreement, including the redacted portions, has been separately filed with the Securities and Exchange Commission.

(B) REPORTS ON FORM 8-K

Not applicable.

16

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 9, 2001

ESPERION THERAPEUTICS, INC.
(Registrant)

By: /s/ Roger S. Newton

Roger S. Newton
President and Chief Executive Officer
(Principal Executive Officer)

By: /s/ Timothy M. Mayleben

Timothy M. Mayleben
Vice President and Chief Financial Officer
(Principal Financial Officer)

17

INDEX TO EXHIBITS

NUMBER	EXHIBIT
10.33	Commercial Sublease between SWMF Holdings Corporation and Esperion Therapeutics, June 22, 2001.
10.34	Lease Extension - Second Renewal Term between Maxey LLC and Esperion Therapeutics September 21, 2001.
10.35@	License Agreement Michigan File 1855 Technology between the Regents of the University of Michigan and Esperion Therapeutics, Inc. dated effective September 18, 2001.

@ Confidential treatment has been requested with respect to the portions of the Agreement indicated with brackets and asterisks [***]. A complete copy of this Agreement, including the redacted portions, has been separately filed with the Securities and Exchange Commission.